Targeting CXCR4-dependent immunosuppressive Ly6Clowmonocytes improves antiangiogenic therapy in colorectal cancer

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

(2017) Keehoon Jung et al.   JOURNAL OF CLINICAL INVESTIGATION

Coinhibitory Pathways in Immunotherapy for Cancer

(2016) Susanne H. Baumeister et al.   Annual Review of Immunology

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses

(2016) Shu Zhen Chong et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Immune-checkpoint blockade — durable cancer control

(2016) Elizabeth I. Buchbinder et al.   Nature Reviews Clinical Oncology

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

(2016) N. N. Rahbari et al.   Science Translational Medicine

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Macrophage PI3K  Drives Pancreatic Ductal Adenocarcinoma Progression

(2016) M. M. Kaneda et al.   Cancer Discovery

Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy

(2015) Harold F. Dvorak   CANCER JOURNAL

CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice

(2015) Qian Liu et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy

(2015) Richard L. Proia et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer and the Immune System: Basic Concepts and Targets for Intervention

(2015) Drew Pardoll   SEMINARS IN ONCOLOGY

Intertwined regulation of angiogenesis and immunity by myeloid cells

(2015) Lee B. Rivera et al.   TRENDS IN IMMUNOLOGY

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

(2015) Yanping Xiao et al.   Cancer Discovery

Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy

(2015) Lee B. Rivera et al.   Cell Reports

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal

(2013) Leo M. Carlin et al.   CELL

Endoscopic Time-Lapse Imaging of Immune Cells in Infarcted Mouse Hearts

(2013) Keehoon Jung et al.   CIRCULATION RESEARCH

Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver

(2013) Yu Zhang et al.   CLINICAL & EXPERIMENTAL METASTASIS

Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow

(2013) Sapna Devi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

(2013) Alicia S Chung et al.   NATURE MEDICINE

Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice

(2012) K. Balabanian et al.   BLOOD

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target

(2012) B. Sitohy et al.   CANCER RESEARCH

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

(2011) D. G. Duda et al.   CLINICAL CANCER RESEARCH

In vivo wide-area cellular imaging by side-view endomicroscopy

(2010) Pilhan Kim et al.   NATURE METHODS

C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells

(2010) S. Hiratsuka et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions

(2009) Kyle J. Eash et al.   BLOOD

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

(2009) L. Xu et al.   CANCER RESEARCH

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo

(2009) Bakhos A Tannous   Nature Protocols

Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases

(2009) Euiheon Chung et al.   PLoS One

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer

(2008) Mallika Ghosh et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS